Based on the Arcutis Biotherapeutics Inc stock forecast from 4 analysts, the average analyst target price for Arcutis Biotherapeutics Inc is USD 18.20 over the next 12 months. Arcutis Biotherapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arcutis Biotherapeutics Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Arcutis Biotherapeutics Inc’s stock price was USD 12.42. Arcutis Biotherapeutics Inc’s stock price has changed by -9.14% over the past week, -15.57% over the past month and +117.51% over the last year.
No recent analyst target price found for Arcutis Biotherapeutics Inc
No recent average analyst rating found for Arcutis Biotherapeutics Inc
Company Overview Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Read Less
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaqu...Read More
Frequently Asked Questions About Arcutis Biotherapeutics Inc (ARQT) Stock
Based on ratings from 4 analysts Arcutis Biotherapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on ARQT's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ARQT is USD 18.20 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 15.
ARQT stock's Price/Earning ratio is -99,999.99.
Our analysis grades ARQT stock's Price / Earning ratio at A. This means that ARQT stock's Price/Earning ratio is above 4.000000000000004% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ARQT may be undervalued for its sector.
The last closing price of ARQT's stock was USD 12.42.
The most recent market capitalization for ARQT is USD 1.60B.
Based on targets from 4 analysts, the average taret price for ARQT is projected at USD 18.20 over the next 12 months.
This means that ARQT's stock price may go up by +46.54% over the next 12 months.
We can't find any ETFs which contains Arcutis Biotherapeutics Inc's stock.
As per our most recent records Arcutis Biotherapeutics Inc has 296 Employees.
Arcutis Biotherapeutics Inc's registered address is 3027 Townsgate Road, Westlake Village, CA, United States, 91361.
You can get more information about it from Arcutis Biotherapeutics Inc's website at https://www.arcutis.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Arcutis Biotherapeutics Inc (ARQT) Stock
Based on ratings from 4 analysts Arcutis Biotherapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on ARQT's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ARQT is USD 18.20 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 15.
ARQT stock's Price/Earning ratio is -99,999.99.
Our analysis grades ARQT stock's Price / Earning ratio at A. This means that ARQT stock's Price/Earning ratio is above 4.000000000000004% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ARQT may be undervalued for its sector.
The last closing price of ARQT's stock was USD 12.42.
The most recent market capitalization for ARQT is USD 1.60B.
Based on targets from 4 analysts, the average taret price for ARQT is projected at USD 18.20 over the next 12 months.
This means that ARQT's stock price may go up by +46.54% over the next 12 months.
We can't find any ETFs which contains Arcutis Biotherapeutics Inc's stock.
As per our most recent records Arcutis Biotherapeutics Inc has 296 Employees.
Arcutis Biotherapeutics Inc's registered address is 3027 Townsgate Road, Westlake Village, CA, United States, 91361.
You can get more information about it from Arcutis Biotherapeutics Inc's website at https://www.arcutis.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARQT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
